Literature DB >> 20349291

[Cardiorenal syndrome].

Jan Galle1.   

Abstract

With increasing age of a population, the rate and severity of comorbidities are also growing, resulting in a rising number of people with a condition described as "cardiorenal syndrome". Initially, cardiorenal syndrome defined the decline in cardiac and renal function due to diminished renal perfusion in the context of heart failure. However, in order to give consideration to the numerous comorbidities, nowadays the definition has been widened. Following a new classification, five types of cardiorenal syndrome are distinguished. Such a differentiation is helpful to find the appropriate therapeutic approach, according to the underlying disease. Therefore, the new classification and modern therapeutic concepts shall be presented here.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20349291     DOI: 10.1007/s00063-010-1023-9

Source DB:  PubMed          Journal:  Med Klin (Munich)        ISSN: 0723-5003


  33 in total

1.  Daily hemodialysis and the outcome of acute renal failure.

Authors:  Helmut Schiffl; Susanne M Lang; Rainald Fischer
Journal:  N Engl J Med       Date:  2002-01-31       Impact factor: 91.245

2.  Effects of sevelamer and calcium-based phosphate binders on mortality in hemodialysis patients.

Authors:  W N Suki; R Zabaneh; J L Cangiano; J Reed; D Fischer; L Garrett; B N Ling; S Chasan-Taber; M A Dillon; A T Blair; S K Burke
Journal:  Kidney Int       Date:  2007-08-29       Impact factor: 10.612

3.  Effects of sevelamer and calcium on coronary artery calcification in patients new to hemodialysis.

Authors:  Geoffrey A Block; David M Spiegel; James Ehrlich; Ravindra Mehta; Jill Lindbergh; Albert Dreisbach; Paolo Raggi
Journal:  Kidney Int       Date:  2005-10       Impact factor: 10.612

4.  Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis.

Authors:  Christoph Wanner; Vera Krane; Winfried März; Manfred Olschewski; Johannes F E Mann; Günther Ruf; Eberhard Ritz
Journal:  N Engl J Med       Date:  2005-07-21       Impact factor: 91.245

5.  Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study.

Authors:  David N Juurlink; Muhammad M Mamdani; Douglas S Lee; Alexander Kopp; Peter C Austin; Andreas Laupacis; Donald A Redelmeier
Journal:  N Engl J Med       Date:  2004-08-05       Impact factor: 91.245

6.  A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease.

Authors:  Marc A Pfeffer; Emmanuel A Burdmann; Chao-Yin Chen; Mark E Cooper; Dick de Zeeuw; Kai-Uwe Eckardt; Jan M Feyzi; Peter Ivanovich; Reshma Kewalramani; Andrew S Levey; Eldrin F Lewis; Janet B McGill; John J V McMurray; Patrick Parfrey; Hans-Henrik Parving; Giuseppe Remuzzi; Ajay K Singh; Scott D Solomon; Robert Toto
Journal:  N Engl J Med       Date:  2009-10-30       Impact factor: 91.245

7.  Right ventricular infarction as an independent predictor of prognosis after acute inferior myocardial infarction.

Authors:  M Zehender; W Kasper; E Kauder; M Schönthaler; A Geibel; M Olschewski; H Just
Journal:  N Engl J Med       Date:  1993-04-08       Impact factor: 91.245

8.  Prognostic value of serum creatinine and effect of treatment of hypertension on renal function. Results from the hypertension detection and follow-up program. The Hypertension Detection and Follow-up Program Cooperative Group.

Authors:  N B Shulman; C E Ford; W D Hall; M D Blaufox; D Simon; H G Langford; K A Schneider
Journal:  Hypertension       Date:  1989-05       Impact factor: 10.190

9.  Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both.

Authors:  Marc A Pfeffer; John J V McMurray; Eric J Velazquez; Jean-Lucien Rouleau; Lars Køber; Aldo P Maggioni; Scott D Solomon; Karl Swedberg; Frans Van de Werf; Harvey White; Jeffrey D Leimberger; Marc Henis; Susan Edwards; Steven Zelenkofske; Mary Ann Sellers; Robert M Califf
Journal:  N Engl J Med       Date:  2003-11-10       Impact factor: 91.245

Review 10.  Cardiorenal syndrome.

Authors:  Claudio Ronco; Mikko Haapio; Andrew A House; Nagesh Anavekar; Rinaldo Bellomo
Journal:  J Am Coll Cardiol       Date:  2008-11-04       Impact factor: 24.094

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.